CD22 and precursor B-cell acute lymphoblastic leukemia: Notably, EBF1, a key regulator of CD22 expression during B-cell differentiation, shows aberrant expression or dysfunction in B-ALL, leading to abnormal CD22 expression and affecting sensitivity to CD22-targeted therapies [96].